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8. There are 55 probiotic products with registered NAPPI
codes available to pharmacies and health shops. Various
independent investigators, among whom is Dr Temmerman
from the University of Ghent, have analysed many different
probiotic products, of which the trade names are cited in the
references.5,10-12 In our opinion, using trade names is upfront,
honest, and enables clear communication with the health care
profession and the consumer needing to be educated to make a
decision about products that contain a number of difficult-to-
pronounce bacterial names (unlike products containing a
generic active like ‘paracetamol’). 
We contend that it is the manufacturer’s and distributor’s
minimum responsibility to ensure that their product complies
with its label claim, and that it is the right of the health care
worker as well as the consumer to know that the probiotic
product recommended or purchased contains what it claims to
contain. Accurate strain identification and viable count are
paramount. Proof of label claims would provide an appropriate
starting point for the industry to assist regulatory bodies in
drawing up guidelines for trustworthy probiotic products.
What needs to follow is a comparative review of the various
claimed health benefits and published literature of the different
probiotic strains.
Gene Elliott
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Probiotics — consensus of
analysis
To the Editor: I have some important issues to raise with
regard to the paper by Elliott and Teversham1 and the rebuttals
and opinions emanating from it.
While traditional starter cultures used in the dairy industry
are selected for their ability to rapidly produce desirable
organoleptic qualities of cultured dairy products, probiotic
bacteria are selected for the potential to provide specific health
or nutritional benefits following consumption. It must be
realised that such a selection addresses several criteria
including safety, technological and functional aspects.2 The
latter aspect has been extensively studied and reviewed, and
the editorial ‘Probiotics — how functional are they?’ by H J
Koornhof in the April SAMJ3 clearly demonstrates the
paramount fact about probiotics: their functionality in terms of
health benefits to man and animal. 
Two frequently overlooked and ignored aspects of safety and
technological difficulties remain. The safety of probiotic strains
is of major importance and guidelines for the safety assessment
have been addressed in several articles.4-6 The prerequisite of
microbiological safety is the identification of the strain. The
current state of evidence includes that probiotic effects are
strain-specific, meaning that correct identification of the strain
level is important to link a strain to a specific health effect as
well as to enable accurate surveillance and epidemiological
studies.7 Furthermore, the origin of the strain and its potential
GRAS (Generally Regarded as Safe) status,8 antibiotic resistance
profile and possible adverse side-effects are a few of the many
issues to be addressed in the process of pre-marketing a
probiotic.
To succeed in promoting the consumption of probiotic
products, the food industry has to meet the demands of the
consumer: in other words all probiotic foods should be safe,
functional and attractive to the senses. Before probiotic strains
can be delivered to consumers, they must first be capable of
being included into industrial fermentations. Next, they need
to survive and retain their functionality during storage as
frozen or freeze-dried cultures as well as in the commercial
food products to which they are added. Finally, the packaging
material and storage conditions are important factors
influencing the quality of the probiotic product during its shelf
life. In most cases, the probiotic properties are affected by the
way in which the strain or culture has been produced,9
meaning that each strain and its production process should be
characterised extensively in order to enable an effective
probiotic product to enter the consumer market. 
Regulatory and product labelling issues in the functional
foods area (probiotics are not considered separately in this
field) primarily involve two concerns: safety and assuring that
product labelling and promotion, while communicating the
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healthful effects of the product, is not misleading. This second
item involves regulation of health claims. In general, a health
claim can be defined as a direct, indirect or implied claim in
food labelling, advertising and promotion that consumption of
a food carries a specific health benefit or avoids a specific
health detriment.10 Regulations are far from unanimous
worldwide, and with regard to certain aspects have evolved
better for animal feed than for human nutrition.11
Besides legislation concerning health claims and labelling
issues, effective on the pre-production phase, suitable
legislation should be established addressing quality control
during and after the production process. It is clear that
regulators worldwide set priority at the health claim level, and
the fact that this topic is far from established indicates that
quality control legislation is still in its infancy. The acronym
‘GMP’ (good manufacturing practice) is used internationally to
describe a set of principles and procedures which, when
followed by manufacturers of mainly therapeutic goods, helps
ensure that the products manufactured will have the required
quality. A basic tenet of GMP is that quality cannot be tested
into a batch of product but must be built into each batch of
product during all stages of the manufacturing process.
Various codes, guides and regulations relating to GMP have
been published by different countries and trade blocks. For
example, the European Union has published a GMP Guide for
Medicinal Products. Most countries use compliance with a
specified GMP requirement as the basis for licensing
manufacturers of medicinal products and medical devices. This
GMP is now being extrapolated towards functional food
manufacturers, although no definitive guidelines have been set up
yet, and quality control is still entirely in the hands of the
manufacturer, who often lacks the required expertise.
In general, a comprehensive approach to shelf life of
probiotic bacteria is tied to maintenance of efficacy. This
implies knowledge of responsible factors and how they are
affected by shelf life. Assuming that efficacy is tied to viability,
the literature suggests that the performance of probiotic-
containing products with regard to shelf life is mixed.10 These
studies provide ‘snapshot’ images of commercial products,
some with little knowledge of storage history, or the analysis of
a limited number of (national) products using sometimes
doubtful identification methods.8,12-14 The need for a definitive
legislation setting guidelines for quality control by manufacturers as
well as by independent research groups is urgent and of utmost
importance, as indicated by the Thematic Priority ‘Food Quality
and Safety’ of the Sixth Framework Programme.15 These
guidelines should state modern standardised analysis methods in
order to facilitate comparison on an international level.
Whereas the majority of research groups worldwide have
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focused on the elucidation of clinical health benefits and
underlying mechanisms of probiotics, I chose to focus on the
development of the abovementioned standardised analysis
method. After 6 years of intensive research, with the aid of in-
house renowned experts in the field of bacterial taxonomy, it is
my opinion that the polymerase chain reaction-denaturing
gradient gel electrophoresis (PCR-DGGE) methodology
designed by myself and a team of expert colleagues shows
reliable and reproducible output. It is important to realise that
a standardised method for the general evaluation of probiotic
products will face difficulties in matching the specificity of
tests designed for the detection of one single strain or product.
However, the PCR-DGGE method used in the study by
Teversham and Elliott has been generally accepted through
publication in renowned international peer-reviewed journals16-22
and is also applied by other research groups.23 It shows highly
reliable results for the identification of bacteria in probiotic
products, although quantification still depends on cultivation
media, generally known to be subject to bias. Future
developments of the method will focus on modern techniques,
such as real-time PCR for quantification and reverse
transcriptase PCR to determine the metabolic activity of the
strains in the product and in situ.
In conclusion, it is crucial that various parties (companies,
scientists, government, journalists) collaborate through
healthy criticism and communication, in order to realise the
one important goal: delivering good quality probiotic
products to the demanding and interested consumer, before
they lose confidence and the probiotic market drops to
insignificant and non-restorable levels.
Robin Temmerman
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Probiotics — the traveller’s
dilemma
To the Editor: We note with interest — and some confusion —
a point made by Paul Anley of Pharma Dynamics in his letter
to SAMJ.1
He questions the method of transport of probiotics sent to
Belgium for an evaluation study.  His products, he states, are
‘particularly sensitive to atmospheric conditions and extremes
of temperature’ and were ‘transported from South Africa under
uncontrolled conditions.’
Are these not the very products recommended for the
overseas traveller, to help alleviate the dreaded traveller’s
diarrhoea?  How then should holidaymakers carry their
medication?
One wonders too how these products withstand the rigours
of their initial journey to South Africa and along the supply
chain into the bathroom cupboard.
We trust the less robust probiotics on the market carry a
warning on the label that they should be transported under
strictly controlled conditions and not be subjected to extremes
of temperature or air pressure. 
Stuart Baines
Travelwell Clinics
3 Medical Centre
30 Victoria Ave
Hout Bay, W Cape
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